Newsroom
TBMC Opens GMP Facility in Zhubei, Marking a New Milestone in Advanced Biomanufacturing
Taiwan Bio-Manufacturing Corporation (TBMC) today held the opening ceremony of its GMP facility in Zhubei, located at the Hsinchu Biomedical Science Park. The facility …
PharmaBoardroom Interview: David Chang, CEO of TBMC, on Scaling Advanced Biomanufacturing in Taiwan
In an interview with PharmaBoardroom, Dr. David Chang, CEO of TBMC, shares his vision to build a leading cell and gene therapy CDMO in Taiwan.
The Chemical Daily: Taiwan Special Feature | Interview with TBMC CEO David Chang
Taiwan Bio-Manufacturing Corporation (TBMC), a CDMO focused on advanced therapeutics, is currently building a GMP-compliant manufacturing facility in the Hsinchu Biomedical Science Park…
TBMC Announces PharmaEssentia’s Investment in Its Series A+ Financing Round
Taiwan Bio-Manufacturing Corporation (TBMC) hereby announces that its Series A+ financing round has secured mid- to long-term investment support from PharmaEssentia Corporation(TWSE:6446), with a total investment amount of up to USD 30 million.
TBMC Expands CRDMO Business with Focus on Four Novel Modalities
Taiwan Bio-Manufacturing Corporation (TBMC) specializes in novel drug modalities, including mRNA vaccines, mRNA therapeutics, and cell and gene therapies. The company is actively advancing its CRDMO services…
TBMC Unveils World-Class CRDMO Vision at BIO Asia–Taiwan 2025
BIO Asia–Taiwan 2025, Taiwan’s well-known biotech exhibition, is taking place from July 24 to 26. Today (July 25), Taiwan Bio-Manufacturing Corporation (TBMC) is hosting a media gathering at its booth to unveil its vision of “Being a World-Class Bio-Manufacturing CRDMO.”
